Apoptosis

Onchilles Pharma Nominates First Drug Development Candidate Leveraging Neutrophil Biology for the Treatment of Cancer

Retrieved on: 
Monday, December 12, 2022

Onchilles also disclosed the expansion of its technology platform to design new therapeutics modulating the M2-like TAMs found in multiple solid tumor indications.

Key Points: 
  • Onchilles also disclosed the expansion of its technology platform to design new therapeutics modulating the M2-like TAMs found in multiple solid tumor indications.
  • ELANE consistently activated this cancer-killing program in more than 40 different cancer cell lines but not in any non-cancer cells tested.
  • To advance this research into a therapeutic, Onchilles generated the N17350 molecule to mobilize the ELANE-mediated cancer-killing pathway.
  • Onchilles Pharma translates breakthrough research in novel innate immune biology to develop first-in-class therapeutics designed to selectively kill tumors and promote a systemic immune response.

Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis

Retrieved on: 
Thursday, December 8, 2022

Vetbiolix completed dose-ranging pharmacokinetic (PK) studies in dogs and determined the optimal efficacy and safety dosage for its upcoming European multicentric clinical study.

Key Points: 
  • Vetbiolix completed dose-ranging pharmacokinetic (PK) studies in dogs and determined the optimal efficacy and safety dosage for its upcoming European multicentric clinical study.
  • Based on these data, Vetbiolix has designed a European Multicentric Clinical study protocol for dogs with osteoarthritis which has been approved by an ethical committee.
  • There is clear need in the market for a safe and effective canine osteoarthritis drug.
  • Vetbiolix has the exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years, during which time Vetbiolix is conducting studies and covering all associated costs.

Insights on the Flow Cytometry Global Market to 2031 - Technological Advancements and High Adoption in Various Research and Diagnostic Applications are Driving Growth

Retrieved on: 
Thursday, December 15, 2022

Flow cytometry technology is widely used in various fields of academic and clinical research, and diagnosis of diseases such as cancer, HIV, and hematological malignancies.

Key Points: 
  • Flow cytometry technology is widely used in various fields of academic and clinical research, and diagnosis of diseases such as cancer, HIV, and hematological malignancies.
  • Major factors that drive growth of the flow cytometry market include technological advancements and high adoption in various research and diagnostic applications.
  • In addition, advent of flow cytometry technology in novel research applications such as cytogenomics, proteomics, and marine biology further supplement the market growth.
  • On the basis of technology, the market is segmented into cell-based flow cytometry and bead-based flow cytometry.

Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH

Retrieved on: 
Monday, December 12, 2022

Pepaxti(melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as the UK.

Key Points: 
  • Pepaxti(melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as the UK.
  • For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
  • On December 7, 2022, the FDA recommended that the Company voluntarily withdraw the US marketing authorization for Pepaxto.
  • Melflufen (melphalan flufenamide) is a lipophilic peptide conjugated alkylating drug that rapidly and selectively delivers cytotoxic agents into tumor cells.

Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH

Retrieved on: 
Monday, December 12, 2022

Pepaxti(melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as the UK.

Key Points: 
  • Pepaxti(melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as the UK.
  • For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
  • On December 7, 2022, the FDA recommended that the Company voluntarily withdraw the US marketing authorization for Pepaxto.
  • Melflufen (melphalan flufenamide) is a lipophilic peptide conjugated alkylating drug that rapidly and selectively delivers cytotoxic agents into tumor cells.

Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors

Retrieved on: 
Thursday, December 1, 2022

The Q901 Phase 1/2 study (NCT05394103) is being conducted at six investigative sites in the U.S., and approximately 70 patients with advanced solid tumors are scheduled to be enrolled.

Key Points: 
  • The Q901 Phase 1/2 study (NCT05394103) is being conducted at six investigative sites in the U.S., and approximately 70 patients with advanced solid tumors are scheduled to be enrolled.
  • The primary objectives of the Phase 1/2 study are to determine the maximum tolerated dose, safety profile, and anticancer efficacy of Q901.
  • Kiyean Nam, Ph.D., CEO of Qurient, commented, The initiation of this study represents a significant milestone for Qurient as it marks the second oncology program to enter into clinical development.
  • Q901 is the companys second oncology drug candidate being developed to treat patients with advanced solid tumors.

Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022

Retrieved on: 
Tuesday, November 29, 2022

New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at World Antiviral Congress 2022 .

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at World Antiviral Congress 2022 .
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property surrounding 3CL proteasebased diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses.
  • 3CL Pharma, through Todos brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir, while also developing the 3CL protease diagnostic TolloTest.

NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance

Retrieved on: 
Tuesday, November 29, 2022

The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.

Key Points: 
  • The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.
  • Based on a unique mode of action of NP137 and biomarker studies conducted in Phase 1, we believe we can enlarge the fraction of responding patients and potentially prevent resistance, said Patrick Mehlen, CEO of NETRIS Pharma.
  • ImmunoNET has been specifically designed by clinicians to provide new solutions for patients suffering from resistance to immune-checkpoint inhibitors.
  • NETRIS Pharma, a clinical-stage company designs and develops anti-cancer therapeutic molecules, particularly monoclonal antibodies, to block the interaction between dependence receptors and their ligands.

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

Retrieved on: 
Sunday, November 27, 2022

*Value as of December 31, 2021

Key Points: 
  • *Value as of December 31, 2021
    MorphoSys will hold its conference call and webcast tomorrow, November 17, 2022, at 2:00pm CET (1:00pm GMT/8:00am EST) to present the results for the third quarter and the first nine months 2022.
  • The statement for the third quarter and the first nine months 2022 (IFRS) are available for download at:
    At MorphoSys, we are driven by our mission to give more life for people with cancer.
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.
  • MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.

Todos Medical to Attend World Antiviral Congress

Retrieved on: 
Tuesday, November 22, 2022

New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that company representatives will attend World Antiviral Congress 2022 .

Key Points: 
  • New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that company representatives will attend World Antiviral Congress 2022 .
  • Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers.
  • Todos two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe.
  • For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.